| Chengdu HuiTai Biomedicine | HuiTai Biomedicine is a leading biotech company committed to the R&D of novel therapeutics for the treatment of Fibrotic Diseases through creating TGF-β superfamily therapeutics based on the precise and targeted regulation of TGF-β signaling. HuiTai is developing innovative therapeutics to address the most severe and difficult-to-treat fibrotic conditions of the lung, liver, kidney, and other organs. |
| Neurophth | Neurophth is China’s first gene therapy company for ophthalmic diseases. As a clinical-stage company, Neurophth is dedicated to discovering and developing gene therapies for patients suffering from blindness and other eye diseases globally. |
| VivaVision Biotech Inc. | Established in August 2016, the company is an innovative pharmaceutical company, focusing on the research and development of innovative drugs for the treatment of ophthalmic diseases. Vivavision is committed to providing new or better treatments for millions of patients with ophthalmic diseases. The company has assembled an internationally well known ophthalmic leadership team, and has established a leading ophthalmic clinical pipeline. |
| Yuanxi Medicine | l A biotech company dedicated to the R&D of chemical drugs for the treatment of diseases such as fibrosis and tumors. l R&D pipelines are mainly focused on the first-in-class drugs with globally novel targets, all of which have independent intellectual property rights globally. The indications are aiming to meet the major unmet clinical needs. |
| Fapon Biopharma | Fapon Biopharma is an innovation-driven leading biopharmaceutical company committed to developing and manufacturing biologics and cell therapy products to fulfill the unmet medical needs for cancer and autoimmune disease treatments. With a team of diverse and experienced scientists, Fapon Biopharma aims to deliver high-quality and affordable innovative medicines to patients and save lives. The company is based in Songshan Lake High-Tech Industrial Park of Dongguan, Guangdong, with an R&D laboratory of 2000 m2 and a new pilot production laboratory of 2000 m2 under construction. An R&D center had also been established in Shanghai, China. The company has built a poweful preclinical platform and a robust R&D pipeline,one or two innovative biological medicines are expected to progress to the IND application stage in the upcoming two years. |
| Fujian Cosunter Pharmaceutical Co., Ltd. | Cosunter Pharmaceutical is a company focusing on the R&D and manufature of anti-HBV (hepatitis B virus) drugs. Founded in June 2001, it has now developed into a leading modern pharmaceutical company with annual sales of over RMB 500 million yuan. All production lines of the company passed the revised GMP certification in August 2014. |
| SciMount Therapeutics | SciMount Therapeutics is a wholly-owned subsidary of XilingLab, focusing on the innovative drug discovery. |
| Hexima Limited | The company (ASX:HXL) is a clinical stage, anti-infectives focused biotechnology company. Its lead product candidate, pezadeftide, is a potential new topical prescription treatment for toenail fungal infections (or onychomycosis). Hexima is currently conducting a 117 patient phase IIb clinical trial. |
| Aptorum Group Limited | The company is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The pipeline of Aptorum is also enriched through (i) the establishment of drug discovery platforms that enable the discovery of new therapeutics assets through, e.g. systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases, and (ii) the co-development of a novel molecular-based rapid pathogen identification and detection diagnostics technology with Accelerate Technologies Pte Ltd, commercialization arm of the Singapore’s Agency for Science, Technology and Research. In addition to the above main focus, we are also pursuing therapeutic projects in neurology, gastroenterology, metabolic disorders, women’s health and other disease areas. We also have projects focused on natural supplements for women undergoing menopause and experiencing related symptoms. We also opened a medical clinic, AML Clinic, in June 2018. |
Jan 6 | GI/Eye/Infectious
BioToChina.org 